Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins

Maryna Perepelyuk, Christina Maher, Ashakumary Lakshmikuttyamma, Sunday A Shoyele Department of Pharmaceutical Science, College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA Abstract: MicroRNAs (miRNAs) are potentially attractive candidates for cancer therapy. However, their ther...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Perepelyuk M, Maher C, Lakshmikuttyamma A, Shoyele SA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	aptamer nanoparticles microRNA lung cancer targeted delivery. Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/2e56db46bd7c4fd595fce7573e714264
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e56db46bd7c4fd595fce7573e714264
record_format	dspace
spelling	oai:doaj.org-article:2e56db46bd7c4fd595fce7573e7142642021-12-02T05:52:55ZAptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins1178-2013https://doaj.org/article/2e56db46bd7c4fd595fce7573e7142642016-07-01T00:00:00Zhttps://www.dovepress.com/aptamer-hybrid-nanoparticle-bioconjugate-efficiently-delivers-mirna-29-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Maryna Perepelyuk, Christina Maher, Ashakumary Lakshmikuttyamma, Sunday A Shoyele Department of Pharmaceutical Science, College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA Abstract: MicroRNAs (miRNAs) are potentially attractive candidates for cancer therapy. However, their therapeutic application is limited by lack of availability of an efficient delivery system to stably deliver these potent molecules intracellularly to cancer cells while avoiding healthy cells. We developed a novel aptamer-hybrid nanoparticle bioconjugate delivery system to selectively deliver miRNA-29b to MUC1-expressing cancer cells. Significant downregulation of oncoproteins DNMT3b and MCL1 was demonstrated by these MUC1 aptamer-functionalized hybrid nanoparticles in A549 cells. Furthermore, downregulation of these oncoproteins led to antiproliferative effect and induction of apoptosis in a superior version when compared with Lipofectamine 2000. This novel aptamer-hybrid nanoparticle bioconjugate delivery system could potentially serve as a platform for intracellular delivery of miRNAs to cancer cells, hence improving the therapeutic outcome of lung cancer. Keywords: aptamer, nanoparticles, microRNA, lung cancer, targeted deliveryPerepelyuk MMaher CLakshmikuttyamma AShoyele SADove Medical PressarticleaptamernanoparticlesmicroRNAlung cancertargeted delivery.Medicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2016, Iss default, Pp 3533-3544 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	aptamer nanoparticles microRNA lung cancer targeted delivery. Medicine (General) R5-920
spellingShingle	aptamer nanoparticles microRNA lung cancer targeted delivery. Medicine (General) R5-920 Perepelyuk M Maher C Lakshmikuttyamma A Shoyele SA Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins
description	Maryna Perepelyuk, Christina Maher, Ashakumary Lakshmikuttyamma, Sunday A Shoyele Department of Pharmaceutical Science, College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA Abstract: MicroRNAs (miRNAs) are potentially attractive candidates for cancer therapy. However, their therapeutic application is limited by lack of availability of an efficient delivery system to stably deliver these potent molecules intracellularly to cancer cells while avoiding healthy cells. We developed a novel aptamer-hybrid nanoparticle bioconjugate delivery system to selectively deliver miRNA-29b to MUC1-expressing cancer cells. Significant downregulation of oncoproteins DNMT3b and MCL1 was demonstrated by these MUC1 aptamer-functionalized hybrid nanoparticles in A549 cells. Furthermore, downregulation of these oncoproteins led to antiproliferative effect and induction of apoptosis in a superior version when compared with Lipofectamine 2000. This novel aptamer-hybrid nanoparticle bioconjugate delivery system could potentially serve as a platform for intracellular delivery of miRNAs to cancer cells, hence improving the therapeutic outcome of lung cancer. Keywords: aptamer, nanoparticles, microRNA, lung cancer, targeted delivery
format	article
author	Perepelyuk M Maher C Lakshmikuttyamma A Shoyele SA
author_facet	Perepelyuk M Maher C Lakshmikuttyamma A Shoyele SA
author_sort	Perepelyuk M
title	Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins
title_short	Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins
title_full	Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins
title_fullStr	Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins
title_full_unstemmed	Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins
title_sort	aptamer-hybrid nanoparticle bioconjugate efficiently delivers mirna-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/2e56db46bd7c4fd595fce7573e714264
work_keys_str_mv	AT perepelyukm aptamerhybridnanoparticlebioconjugateefficientlydeliversmirna29btononsmallcelllungcancercellsandinhibitsgrowthbydownregulatingessentialoncoproteins AT maherc aptamerhybridnanoparticlebioconjugateefficientlydeliversmirna29btononsmallcelllungcancercellsandinhibitsgrowthbydownregulatingessentialoncoproteins AT lakshmikuttyammaa aptamerhybridnanoparticlebioconjugateefficientlydeliversmirna29btononsmallcelllungcancercellsandinhibitsgrowthbydownregulatingessentialoncoproteins AT shoyelesa aptamerhybridnanoparticlebioconjugateefficientlydeliversmirna29btononsmallcelllungcancercellsandinhibitsgrowthbydownregulatingessentialoncoproteins
_version_	1718400162864300032

Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins

Ejemplares similares